Ultime notizie per Western Resources (OTC:WTRNF) Azioni

Western Resources Corp is a resource company focused on the development of its potash project in Canada owned by its wholly owned subsidiary, Western Potash Corp, located in Southern Saskatchewan. Its objectives are to complete Phase I of the Milestone Project to prove a new mining technology, which will then be applied to Phases 2 and 3 to develop potash deposits in an environmentally friendly model. The company's two reportable operating segments are the acquisition, exploration, and development of mineral properties and the investment in real estate projects in Canada.

WESTERN RES CORP by Western Resources Corp.

Western Resources Corp

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) stock has soared nearly 500% over the past year driven by its positioning in the AI space. One analyst believes the stock has a lot more runway ahead with the AI revolution still <a href="https://www.benzinga.com/government/regulations/25/05/45403100/bullish-for-nvidia-tesla-palantir-microsoft-alphabet-amazon-ai-revolution-is-coming-to-the-saudi-kingdom-says-wedbushs-dan-ives">in its early stages</a>.
What To Know: Wedbush&#8217;s Dan Ives famously calls Palantir the &#8220;Messi of AI&#8221; because he expects the company to be one of the biggest beneficiaries of the AI boom. He&#8217;s been right so far, and he&#8217;s not pulling back on his bullish stance in the slightest.
Wednesday on CNBC&#8217;s &#8220;Squawk On The Street,&#8221; Ives predicted that Palantir stock will more than triple in the coming years and trade above $400 per share.
&#8220;That&#8217;s why it&#8217;s the &#8216;Messi of AI.&#8217; I believe we&#8217;re talking about a trillion-dollar market cap for Palantir in the next few years, and I think when you look at what [Alex] Karp and Palantir are doing, they, along with Nvidia, will be leading the AI revolution,&#8221; Ives said.
The other massive beneficiary of AI has been NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which is scheduled to report earnings after the market close on Wednesday. Ives expects the results to act as a &#8220;bright green light&#8221; for tech investors as demand continues to easily outweigh supply. 
There&#8217;s only one chip in the world fueling the AI revolution and that&#8217;s Nvidia&#8217;s, Ives said, adding that AI is driving the fourth Industrial Revolution. He expects Nvidia&#8217;s quarterly report to be the catalyst that kicks off a run to new highs for tech.
Check This Out: <a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a>
Many analysts disagree with Ives on Nvidia and Palantir, especially Palantir, given its massive surge over the past year and its becoming one of the best-performing names in the S&amp;P 500.
Ives told CNBC that many analysts hated Palantir when it hit $25, despised it when it hit $50 and $100, but the deals keep coming in and the company is doing it without a traditional sales team. 
&#8220;I believe it&#8217;s a trillion dollar market cap in the next two to three years, and I think look, haters hate on this one, but I think they continue to underestimate the pure success that they&#8217;re seeing,&#8221; Ives said. 
&#8220;Karp, he&#8217;s playing chess, others are playing checkers. And I think you are starting to realize more and more in government, enterprise, and that&#8217;s why you cannot talk AI revolution without saying Palantir.&#8221;
In order for Palantir to reach a $1 trillion market cap valuation, the stock would need to climb to $427.35 per share. Palantir had a market cap of $291.19 billion as of Tuesday&#8217;s close. 
PLTR Price Action: <a href="http://benzinga.com/quote/PLTR">Palantir shares</a> were up 1.15% at $124.81 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45636050/palantir-partners-with-bain-company-to-accelerate-global-enterprise-ai-adoption">Palantir Partners With Bain &amp; Company To Accelerate Global Enterprise AI Adoption</a></li>
</ul>
Photo: slyellow/Shutterstock.

Analyst Color

Long Ideas

News

Trading Ideas

NVDA

PLTR

Tech Analyst Expects Palantir Stock To Rise Above $400 As AI Revolution  Kicks Into Gear

<a href="https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee" title="https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee">https://www.ft.com/content/2c0db765-03ac-4820-8a02-806469848bee</a>

ASML

AVGO

INTC

LSCC

NXPI

QCOM

RMBS

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

President Trump Orders US Chip Designers To Stop Selling To China, FT Reports

On Wednesday, William Blair initiated coverage on Ultragenyx Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RARE#NASDAQ">RARE</a>), a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">rare genetic diseases</a>.
Since 2017, the company has commercialized four products, which generated $560 million in revenue in 2024, up 29% year-over-year. In the first quarter of 2025, sales increased <a href="https://www.benzinga.com/pressreleases/25/05/g45234765/ultragenyx-reports-first-quarter-2025-financial-results-and-corporate-update" target="_blank" rel="noreferrer noopener">28% to $139.29 million</a>.
Ultragenyx expects fiscal 2025 sales of $640 million-$670 million versus <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $655.02 million</a>.
&#8220;We anticipate Ultragenyx&#8217;s legacy products will continue to provide a strong revenue foundation for the company through the early 2030s,&#8221; writes William Blair analyst Sami Corwin.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44523017/ultragenyx-is-uniquely-positioned-in-long-term-remains-on-jpmorgans-focus-list" rel="noreferrer noopener">Ultragenyx Stays On JPMorgan&#8217;s Focus List As Analyst Highlights Strong Long-Term Positioning</a>
William Blair initiated coverage <a href="https://www.benzinga.com/quote/RARE/analyst-ratings">with an Outperform rating</a>, writing that the company is at an inflection point. Potentially, six additional therapeutics will be approved by the end of 2028, including three approvals in the next 18 months.
Corwin notes that these additional assets synergize with Ultragenyx&#8217;s existing commercial portfolio, aiding in strong commercial launches. She projects the company&#8217;s expanding revenue stream, supplemented by the potential receipt of three priority review vouchers, could enable the company to achieve GAAP profitability in 2027 and beyond.
William Blair noted that regulatory decisions and clinical data could be catalysts for the stock in the near term. Specifically, positive results from the Phase 3 trial of setrusumab in osteogenesis imperfecta (OI) could lead to significant upside.
Corwin projects the products could begin contributing to the top line as early as the fourth quarter of 2025 and could lead to a major revenue inflection in 2026 with the potential approval of pertuzumab in OI.
William Blair views setrusumab as a blockbuster product and estimates peak revenue of $2.4 billion in 2037, $1.4 billion of which will go to Ultragenyx.
Price Action: RARE stock is down 1.65% at $34.50 at the last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45629309/why-is-rare-lung-disease-focused-savara-stock-trading-lower-on-tuesday" target="_blank" rel="noreferrer noopener">Why Is Rare Lung Disease-Focused Savara Stock Trading Lower On Tuesday?</a></li>
</ul>
Photo: Shutterstock

Biotech

Health Care

Initiation

Analyst Ratings

General

RARE

Analyst Bullish On Ultragenyx, Poised For Growth With Six Drug Approvals Expected By 2028

Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares are trading higher on Wednesday after the company announced the appointment of a new CEO on Tuesday, and&nbsp;<a target="_blank" href="https://www.benzinga.com/general/sports/25/05/45632213/vail-resorts-stock-climbs-after-company-announces-ceo-transition" rel="noreferrer noopener">reaffirmed 2025 guidance.</a>
Vail Resorts announced that&nbsp;Rob Katz, executive chair and former CEO, has been appointed current CEO. Katz will succeed&nbsp;Kirsten Lynch, who has stepped down as CEO and as a director of the board.
Here are the key analyst takes on the development:
<ul class="wp-block-list">
<li>JP Morgan analyst Matthew R. Boss upgraded the stock from Underweight to Neutral, with a price forecast of $167.</li>
<li>BofA Securities analyst Shaun C. Kelley reiterated the Neutral rating on the stock, raising the price forecast from $160 to $175.</li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45645056/gold-etf-bleeds-money-at-fastest-pace-in-3-years-is-the-safe-haven-trade-over" rel="noreferrer noopener">Gold ETF Bleeds Money At Fastest Pace In 3 Years — Is The Safe-Haven Trade Over?</a>
<h2 class="wp-block-heading">JP Morgan</h2>
JP Morgan analyst Boss stated in the analyst note that with Vail Resorts nearing the end of industry normalization challenges by FY25 and former CEO Katz returning to lead, the company may be approaching an inflection point in both revenue and earnings.
This outlook is backed by unique growth drivers, Vail Resorts's portfolio of top-tier resorts—including the five most visited in North America—and its advance commitment strategy through various Epic Pass options, which helps reduce seasonal risk.
Boss sees a unique chance for the firm to accelerate its model under returning CEO Katz, who previously led Vail Resorts from 2006 to 2021 and now resumes his leadership role.
With a history of driving double-digit EBITDA growth over 15+ years and a focus on meaningful, quality-driven expansion, Katz may help the company recapture around 250bps of EBITDA margin versus FY19 through stronger operating leverage.
<h2 class="wp-block-heading">BofA Securities</h2>
Bank of America analyst Kelley writes that Katz's return signals urgency, highlighted by a 10% after-hours stock jump and expectations of renewed revenue momentum.
While major shifts to Vail's commitment strategy, efficiency plans, or dividend approach seem unlikely for now, Katz, who previously led transformative initiatives like the Epic Pass and M&amp;A, could drive reinvention, given his role in shaping the industry's current model.
Price Action: MTN shares are trading higher by 12% to $169.66 at last check Wednesday.
Now Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45655193/applovins-valuation-reflects-high-expectations-for-monetization-expansion-analyst" target="_blank" rel="noreferrer noopener">AppLovin&#8217;s Valuation Reflects High Expectations For Monetization Expansion: Analyst</a></li>
</ul>
Photo by Simone Hogan via Shutterstock

Equities

Upgrades

Price Target

Markets

Movers

Vail Resorts CEO Shake-Up Spurs Hopes Of Growth Rebound

JPMorgan analyst Sebastiano Petti maintained an Overweight rating on United States Cellular (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>) and lowered the<a href="https://www.benzinga.com/quote/usm/analyst-ratings" target="_blank" rel="noreferrer noopener"> price forecast from $88 to $85</a>.
The analyst says that he foresees additional opportunities to unlock value and anticipates substantial capital returns for shareholders within the next year.
The analyst notes the commencement of T-Mobile&#8216;s exchange offer for up to $2.044 billion of US Cellular debt, which he believes indicates the deal&#8217;s imminent close in the coming weeks, as such offers typically <a target="_blank" href="https://www.benzinga.com//node/43883619" rel="noreferrer noopener">precede closing within 40 days</a>.
Consequently, Petti now expects T-Mobile&#8217;s acquisition of US Cellular&#8217;s wireless operations to finalize on July 1, aligning with expectations for a mid-2025 close.
The analyst now estimates that the company could distribute up to $28-$30 per share in special dividends by mid-2026.
This comprises of an estimated $9-$11 per share from the T-Mobile deal, an additional $10 per share following the sale of spectrum to AT&amp;T, and $9 per share from the Verizon spectrum deal, says the analyst.
The analyst notes that USM continues its focus on cost optimization, but increased industry-wide competition is expected to impact its 2025 financials.
Petti raised the 2025 service revenue estimate to $2.95 billion (up 0.3%) due to higher postpaid ARPU, which is projected to grow 1.2% year-over-year to $52.44, despite anticipated lower volumes in postpaid, handset, and prepaid segments.
Conversely, the analyst lowered 2025 EBITDA estimate by 3% to $970 million, resulting in margins of 26.4% (down from 26.9%).
Although first-quarter capital spending was significantly below the expectations ($53 million versus $133 million prior), the analyst is only marginally trimming 2025 capital expenditure by 2% to $520 million.
Price Action: USM shares are down 0.76% at $62.80 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45465922" target="_blank" rel="noreferrer noopener">Charter Seals&nbsp;$34.5 Billion&nbsp;Cox Merger Deal, Creating Powerhouse To Battle Streaming, Wireless Rivals</a></li>
</ul>
Photo: Shutterstock

Large Cap

US Cellular Deal Could Unlock Major Payouts: JPMorgan Expects T-Mobile Acquisition To Finalize By July

Stock Split

VXRT

Vaxart Board Commits To High End Of 1-for-20 Reverse Stock Split Ratio

Needham analyst Bernie McTernan <a target="_blank" href="https://www.benzinga.com/quote/APP/analyst-ratings" rel="noreferrer noopener">reiterated its Hold rating</a> on AppLovin Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) on Wednesday.
AppLovin&#8217;s primary tool for future growth is <a target="_blank" href="https://www.benzinga.com/insights/analyst-ratings/25/05/45642953/where-applovin-stands-with-analysts" rel="noreferrer noopener">Axon 2</a>, which is an ad optimizer operating within the DSP that allows advertisers to place ads according to specified return thresholds.
In McTernan&#8217;s third AppLovin Ecommerce Tracker, the total number of websites in his sample using Axon grew by +3% compared to last month to 323, which includes 18 gross adds and 7 churns.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45323056/applovins-rapid-ad-growth-ai-gains-drive-hike-in-analyst-price-forecast" rel="noreferrer noopener">AppLovin&#8217;s Rapid Ad Growth, AI Gains Drive Hike In Analyst Price Forecast</a>
The seven churned websites were more than the one churn last month, the analyst noted. However, two of the seven companies shut down their businesses, he said in the analyst note.
McTernan said Apparel, Footwear &amp; Accessories was the largest category gainer in the past month, with 10 gross adds and one churn.
The analyst noted that AppLovin announced in December that the company had 600 e-commerce brands and a $1 billion ad spend run rate.
Given the relatively modest growth and essentially unchanged pixel helper count, he does not believe self-service has launched yet.
McTernan noted one big brand add the Pixel this month, Reebok, which Authentic Brands Group, a private brand management company, owns. Press reports indicate Reebok does ~$5 billion in sales, which is in the bottom quartile for revenue among the 70 big brands he sampled. Authentic Brands Group combined for $32 billion+ of revenue, the analyst said. Some of the brands that added the Pixel include Champion, Juicy Couture, and Vince Camuto, he said.
Other brands ABG owns but not using the Pixel include Nautica, Aeropostale, Lucky, Brooks Brothers, Sperry, Spyder, Ted Baker, Forever 21, Hunter, McTernan noted.
As a reminder, the analyst noted that focusing on some of the larger brands in his dataset is essential as they have the most remarkable ability to scale advertising spending on the platform. He considered ~70 websites in his tracker big brands.
McTernan noted no change to AppLovin&#8217;s reported user count for the Axon pixel at 2k. The analyst noted that the user count crossed from 1k to 2k between February 28 and March 5, which he noted means the user count passed 1,500 that week.
AppLovin projected second-quarter revenue of $1.21 billion and EPS of $1.86.
Weighing in on AppLovin&#8217;s valuation, McTernan stated that the company&#8217;s valuation has become one of the most expensive within their coverage group. This surge is driven by heightened expectations for the company&#8217;s ability to further monetize its advertising platform through new verticals, he noted.
Price Action:&nbsp;APP stock is trading higher by 1.29% to $385.83 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45380609" target="_blank" rel="noreferrer noopener">AppLovin Stock Surges On Strong Q1 Earnings And Tariff Truce Tailwinds</a></li>
</ul>
Photo by Piotr Swat via Shutterstock

Reiteration

Tech

AppLovin's Valuation Reflects High Expectations For Monetization Expansion: Analyst

BHVN

Biohaven Announces Plans To Initiate Pivotal Trials In Graves' Disease And In IgA Nephropathy In 2H 2025 And 1H 2026

On Friday, BOfA Securities analyst hosted Richard Aboulafia, a partner at AeroDynamic Advisory, to discuss expectations <a href="https://www.benzinga.com/analyst-ratings/analyst-color" target="_blank" rel="noreferrer noopener">for the upcoming 2025 Paris Air Show</a>.
The analyst says that regarding news of potential 50% EU tariffs, Aboulafia warned that the Air Show could foreshadow how future <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45585283/trump-tariff-threat-hits-europe-stocks-sink-as-50-duties-loom" target="_blank" rel="noreferrer noopener">international negotiations might unfold</a>.
The analyst notes that the EU might draw lessons from recent agreements in China and the Middle East, which mainly included aerospace and defense products.
Nevertheless, the analyst writes that given the EU&#8217;s own substantial aerospace and defense industry, which it aims to protect, U.S. aerospace and defense interests might become a point of contention rather than an incentive in these discussions.
Also Read: <a href="https://www.benzinga.com//node/45594990" target="_blank" rel="noreferrer noopener">DOJ Offers Boeing Deal To Avoid Criminal Charges Over 737 Max Crashes</a>
Regarding Boeing Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>), Aboulafia views recent deals in the Middle East and China as setting a precedent for other nations&#8217; trade negotiations, suggesting orders will be held back as bargaining chips, noted the analyst.
The analyst writes that, for both Airbus SE (OTC:<a class="ticker" href="https://www.benzinga.com/stock/EADSY#OTC">EADSY</a>) and Boeing, Aboulafia doesn&#8217;t foresee many airlines placing large new orders, primarily due to a lack of new aircraft programs and existing backlogs exceeding 10 years for their most popular models.
Further, the analyst noted that, as previously disclosed, Aboulafia doesn&#8217;t anticipate any major new commercial aircraft program unveilings due to ongoing supply chain issues and global macroeconomic constraints.
In the defense sector, Aboulafia expects numerous companies to compete for subsystem roles on programs like NGAD/the F-47 and CCA.
Additionally, Aboulafia anticipates an outsized presence of unmanned aerial systems at the show, predicting a focus on lower-tech, expendable variants rather than highly sophisticated systems, says the analyst.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com//node/45583103" target="_blank" rel="noreferrer noopener">Trump&#8217;s Chosen Air Force One Contractor L3Harris To Pay $62 Million As Settlement For Misleading US Military</a></li>
</ul>
Photo: Shutterstock

European Aeronautic Defence And Space Unsponsored

EADSY

Will Paris Air Show Signal Shift In Aerospace Trade? Analyst Flags EU Tariff Risks, Order Delays

In a corporate cage match, two of the globe&#8217;s most dominant oil titans are fighting it out for a share of one of the world&#8217;s most coveted oil finds: Guyana. But while Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>) and Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) are in the midst of arbitration, ETF investors may need to hold on tight. This courtroom battle could rock some of the <a href="https://www.benzinga.com/etfs">largest energy ETFs available</a>.
<h1 class="wp-block-heading">The Stakes: Oil, Ego — And An 11 Billion Barrel Bonanza</h1>
Behind the fight is Hess Corp&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>) 30% interest in a huge Guyanese oil project, which has roughly 11 billion barrels in projected reserves. Chevron said in 2023 it agreed to buy Hess for $53 billion, a transaction that would put it at the front of the Guyana boom. 
But Exxon, which already <a href="https://www.benzinga.com/markets/equities/24/06/39479711/exxon-mobil-rakes-in-billions-from-guyana-oil-deal-net-margin-tops-chip-giant-report">co-leads the Guyana project</a>, says it has pre-emptive rights to the stake. Arbitration gets underway in London this week, and sometime in late summer, a panel will <a href="https://www.benzinga.com/topic/oil">make a decision</a>.
<h1 class="wp-block-heading">ETF Fallout: Who&#8217;s Exposed To What?</h1>
The heavy hitters such as Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>), iShares U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYE#NYSE">IYE</a>) and Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>) are carrying heavy loads of both Exxon and Chevron, between 35% and 40% combined weighting in each fund.
If either Exxon or Chevron prevails, one can anticipate a pop for these ETFs as the Guyana deal would mean long-term growth assets for the prevailing company.
Hess Corp. is smaller but essential in this saga. ETFs such as iShares U.S. Oil &amp; Gas Exploration &amp; Production ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/IEO#BATS">IEO</a>) carry meaningful exposure to Hess, and therefore a front-row seat to either a lucrative M&amp;A payday or a disappointing fizz.
Additionally, merger arbitrage ETFs, such as NYLI Merger Arbitrage ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MNA#NYSE">MNA</a>) and ProShares Merger ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/MRGR#BATS">MRGR</a>), are likely to be betting on the Hess factor already. If the transaction gets delayed or blocked further, one can expect some readjustment.
<h1 class="wp-block-heading">Beyond the Big Oil Bets</h1>
As Chevron cuts jobs and balances new resources in Kazakhstan and the Gulf of Mexico, it also deals with <a href="https://www.benzinga.com/markets/25/02/44000386/trump-shuts-down-chevrons-venezuela-oil-permit-tightening-pressure-on-maduro-regime-crude-oil-prices-rise-on-supply-concerns">uncertainty in Venezuela</a>, where an operating license may be withdrawn. Exxon is increasing <a href="https://corporate.exxonmobil.com/locations/guyana/guyana-project-overview">production </a>in Guyana to 1.3 million barrels/day by 2027, greater than North Dakota&#8217;s Bakken Shale.
<h1 class="wp-block-heading">One Wrong Move = ETF Domino Effect</h1>
With activist investors watching Exxon and Chevron still under pressure to prove long-term growth, the arbitration&#8217;s outcome could drive major portfolio re-weightings, flows into specific funds or a rise in thematic oil and gas ETFs.
In short, this isn't just a battle over barrels, it's about which ETFs end up doing well and which might need a Band-Aid.
<h1 class="wp-block-heading">Final Thought</h1>
This Guyana brawl might be happening in a London arbitration chamber, but its aftershocks will be felt through world markets and ETF tickers. For investors, it&#8217;s time to look beyond the barrel and begin peering at the ticker tape.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45647794/why-kre-is-falling-behind-xlf-and-raising-flashbacks-of-the-svb-collapse-etf-market-senses-bank-trouble">KRE Falls Behind XLF, Sparks SVB Collapse Flashbacks: Are ETFs Sensing Bank Trouble?</a></li>
</ul>
Photo: Shutterstock

Sector ETFs

Commodities

Legal

Global

ETFs

iShares Dow Jones US Oil & Gas Exploration & Production Index Fund

iShares Dow Jones US Energy Sector Index Fund

MRGR

Exxon Stock Vs. Chevron: The 11 Billion Barrel Oil War That Could Shake Up Energy ETFs

MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) shares are trading higher Wednesday, continuing a sharp upward move fueled by retail momentum and recent announcements about the company's<a href="https://www.benzinga.com/trading-ideas/movers/25/05/45622723/microcloud-hologram-stock-is-moving-higher-tuesday-whats-going-on"> progress in quantum technologies</a>.
What To Know: MicroCloud Hologram shares have gained over 80% during intraday trading Wednesday, with volume exceeding 43 million shares, well above its 100-day average of 1.1 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
The rally appears to be retail-driven as traders highlight the company's recent quantum initiatives. 
Last week, MicroCloud disclosed it had developed a new quantum supervised learning method, indicating it addresses key limitations in current quantum machine learning algorithms. The company also reported advances in quantum-enhanced imaging, specifically using holographic LiDAR based on time-frequency entanglement to achieve a 40dB signal-to-noise ratio. This technology advancement reportedly enables imaging of non-reflective targets in noisy environments.
The recent developments have gained traction on social media platforms as retail traders react to both the technical potential and the stock's low float. Only 4.73 million shares are available for public trading, and 13.52% of the float is currently sold short, which is likely contributing to increased volatility in the name. Institutional ownership remains minimal at just 0.32%, underscoring the retail-driven nature of the move.
Despite the current rally, MicroCloud shares remain down nearly 95% year-to-date. The stock hit a 52-week low of $5.37 last week before reversing course. The ongoing momentum highlights how small-cap, low-float stocks like MicroCloud can see sharp price increases in response to news flow combined with increasing retail interest.
HOLO Price Action: MicroCloud Hologram shares were up 82.8% at $11.04 at the time of publication Wednesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45651401/wall-street-stalls-as-treasury-yields-climb-again-ahead-of-nvidia-earnings-fed-minutes-whats-driving-markets-wednesday">Wall Street Stalls As Treasury Yields Climb Again Ahead Of Nvidia Earnings, Fed Minutes: What&#8217;s Driving Markets Wednesday? </a></li>
</ul>
Image: Shutterstock.

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

MicroCloud Hologram Stock Is Surging Again: What's Going On?

<ul>
<li>Optimized subcutaneous (SC) administration of BHV-1400 achieved rapid, deep, selective, and sustained lowering of Gd-IgA1, differentiating Biohaven's leading TRAP degrader for IgAN from the complement and BLyS/APRIL inhibitor competition.
<ul>
<li>Up to 81% reduction of Gd-IgA1 was observed, with reductions from baseline sustained for weeks after a single SC dose administration.</li>
<li>BHV-1400 brings precision immunology to the treatment landscape of IgAN as it was rationally designed to selectively remove galactose-deficient IgA1 (Gd-IgA1), the pathogenic antibody driver of the disease while sparing healthy antibodies IgA, IgG, IgE, and IgM.</li>
<li>Preservation of immunoglobulins, the complement system, and cell-mediated and humoral immunity offers key differentiation against immunosuppressive BLyS/APRIL inhibitors, complement inhibitors, and budesonide.</li>
<li>Based upon the rapid and deep reductions of Gd-IgA1 observed with subcutaneous BHV-1400, Biohaven plans to study BHV-1400 in patients with IgAN, initiating a pivotal trial in 2026 using urine protein-creatinine ratio (UPCR) as a surrogate endpoint for accelerated approval.</li>
</ul>
</li>
<li>Optimized SC administration of BHV-1300 has continued to demonstrate rapid, deep, and sustained lowering of total IgG in Phase 1 studies.
<ul>
<li>Recently generated clinical data shows that BHV-1300 achieved rapid, deep, and sustained lowering of total IgG, with reductions up to 87%.</li>
<li>Median maximum reductions of 83% were observed within 18 days of the first subcutaneous dose.</li>
<li>The range of IgG reductions possible with varying dosing paradigms of BHV-1300 allows for tunable dosing regimens tailored for acute and chronic disease management, with higher doses for acute disease management and lower, less frequent dosing for chronic disease management.</li>
<li>Based upon the rapid and deep reductions of IgG and favorable tolerability profile observed with BHV-1300, Biohaven plans to study BHV-1300 in patients with Graves' Disease and initiate pivotal trials in 2H 2025.</li>
</ul>
</li>
</ul>
NEW HAVEN, Conn., May 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BHVN#NYSE">BHVN</a>) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today highlighted the success of its first MoDE&#x2122; and TRAP&#x2122; degraders in achieving key target pharmacodynamic endpoints and announced plans to initiate pivotal trials in Graves' Disease and in IgA nephropathy in 2H 2025 and 1H 2026, respectively at Biohaven's 2025 R&amp;D Day, held concurrently with the Yale Innovation Summit in New Haven, Connecticut. The presentation slides from Biohaven's R&amp;D day for the TRAP and MoDE degraders and its other platforms will be available on the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4437235-1&amp;h=3793265758&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D4177529-1%26h%3D1652257103%26u%3Dhttps%253A%252F%252Fir.biohaven.com%252Fevents-presentations%252Fevents%26a%3DEvents%2Band%2BPresentations%2Bpage&amp;a=Events+and+Presentations+page">Events and Presentations page</a> of the Biohaven website just prior to their presentations.
 &nbsp;

Biohaven Showcases MoDE And TRAP Degrader Innovations at R&D Day

Flying cars &#8211; technically, electric vertical takeoff and landing vehicles, or eVTOLs &#8211; are inching <a href="https://www.benzinga.com/topic/air-mobility">closer to liftoff</a>. But for investors in names like Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) and Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>), JPMorgan's latest insight is clear: the long-term runway looks promising, but near-term turbulence is hard to avoid.
JPMorgan analyst Bill Peterson, after a conversation with McKinsey's Robin Riedel, said the eVTOL dream is alive—just not quite ready for boarding. Commercial service may begin in the next 12–18 months, but mass adoption likely won't arrive until the mid-2030s. The market could top $1 trillion down the line, but initial revenues are expected to hover in the premium niche—think high-end urban air mobility, priced like Uber Black.
That modest start comes with high-stakes hurdles: regulatory certification, vertiport buildout, and propulsion tech reliability. Joby and Archer are making headway—Joby with successful test flights, and Archer inching toward piloted trials. Still, certification remains a heavy lift.
<h2 class="wp-block-heading">Joby Lands A Lift From Toyota</h2>
One tailwind for Joby came this week via a <a href="https://www.benzinga.com//node/45643642">$250 million boost from </a><a href="https://www.benzinga.com//node/45643642">Toyota</a> Motor Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), closing the first tranche of a strategic investment meant to support certification and commercial production. The capital also strengthens their long-term manufacturing alliance.
"With this capital and Toyota's legendary production expertise, we're enhancing our ability to scale," said Joby CEO JoeBen Bevirt, noting the progress already made streamlining design and production with Toyota's help.
Read Also: <a href="https://www.benzinga.com/news/25/05/45501045/archer-aviation-achr-stock-retreats-after-strong-rally-whats-going-on">Archer Aviation (ACHR) Stock Retreats After Strong Rally: What&#8217;s Going On?</a>
<h2 class="wp-block-heading">Archer Hit By Short Seller Turbulence</h2>
Meanwhile, Archer faces headwinds. Short seller <a href="https://www.benzinga.com//node/45521011">Culper Research accused</a> the company of misleading investors with exaggerated claims about its Midnight Edition eVTOL. Culper questioned the aircraft's transition flight performance and called its commercialization timeline "reckless."
JPMorgan remains cautious. Overseas players—especially in China and the Middle East—may outpace U.S. firms due to aligned governments and deeper funding. 
And while trillion-dollar headlines grab attention, JPMorgan sees a smaller, slower takeoff in the near term.
The sky&#8217;s the limit, but Joby and Archer aren't cleared for cruising altitude just yet.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45644145/nvidia-stock-is-bullish-ahead-of-q1-earnings-but-will-h20-chip-woes-dampen-the-party">Nvidia Bullish Ahead Of Q1 Earnings, But Will H20 Chip Woes Dampen The Party?</a></li>
</ul>
Photo: Shutterstock

ACHR

JOBY

Joby, Archer: Flying Cars On A $1 Trillion Runway, But Still Not Cleared For Takeoff

Bank of New York Mellon (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BK#NYSE">BK</a>) underwent analysis by 9 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $91.56, a high estimate of $98.00, and a low estimate of $85.00. This current average reflects an increase of 1.98% from the previous average price target of $89.78. 
<img src="https://www.benzinga.com/files/images/story/2025/1748458880_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bank of New York Mellon. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$97.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$94.00</td>
<td>$98.00</td>
</tr>
<tr>
<td>David Smith</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$98.00</td>
<td>$99.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>In-Line</td>
<td>$87.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Whit Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$96.00</td>
<td>$86.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Bank of New York Mellon. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Bank of New York Mellon compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Bank of New York Mellon's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Bank of New York Mellon's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bank of New York Mellon analyst ratings.</a>
<h2>Get to Know Bank of New York Mellon Better</h2>
BNY Mellon is a global investment company involved in managing and servicing financial assets throughout the investment lifecycle. The bank provides financial services for institutions, corporations, and individual investors and delivers investment management and investment services in 35 countries and more than 100 markets. BNY Mellon is the largest global custody bank in the world, with $52.1 trillion in under custody or administration (as of December 2024), and can act as a single point of contact for clients looking to create, trade, hold, manage, service, distribute, or restructure investments. BNY Mellon's asset-management division manages about $2.0 trillion in assets.
<h3>Financial Milestones: Bank of New York Mellon's Journey</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Bank of New York Mellon's revenue growth over a period of 3M has been noteworthy. As of 31 March, 2025, the company achieved a revenue growth rate of approximately 5.78%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 24.51%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Bank of New York Mellon's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.27%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Bank of New York Mellon's debt-to-equity ratio is below the industry average. With a ratio of 0.87, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Analyst Ratings: What Are They?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Bank of New York Mellon: Insights From 9 Analyst Reviews

Ratings for Oxford Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXM#NYSE">OXM</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Oxford Industries and provided 12-month price targets. The average target is $60.57, accompanied by a high estimate of $80.00 and a low estimate of $47.00. A decline of 15.68% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748458864_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Oxford Industries. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joseph Civello</td>
<td>Truist Securities</td>
<td>Announces</td>
<td>Hold</td>
<td>$56.00</td>
<td>-</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$52.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Sell</td>
<td>$47.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Mauricio Serna</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$64.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$68.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Alex Markgraff</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$80.00</td>
<td>$95.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Oxford Industries. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Oxford Industries compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Oxford Industries's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Oxford Industries's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OXM/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Oxford Industries analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Oxford Industries</h2>
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
<h3>Oxford Industries: A Financial Overview</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Oxford Industries's financials over 3M reveals challenges. As of 31 January, 2025, the company experienced a decline of approximately -3.44% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Oxford Industries's net margin is impressive, surpassing industry averages. With a net margin of 4.58%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Oxford Industries's ROE stands out, surpassing industry averages. With an impressive ROE of 2.9%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.42%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.72, Oxford Industries adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 7 Analyst Projections For Oxford Industries

Deep-pocketed investors have adopted a bullish approach towards Humana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in HUM usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 29 extraordinary options activities for Humana. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 58% leaning bullish and 31% bearish. Among these notable options, 11 are puts, totaling $575,520, and 18 are calls, amounting to $1,092,502.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $370.0 for Humana, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Humana's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Humana's significant trades, within a strike price range of $200.0 to $370.0, over the past month.
<h3>Humana Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748458863_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/13/25</td>
<td>$7.2</td>
<td>$7.0</td>
<td>$7.0</td>
<td>$245.00</td>
<td>$216.8K</td>
<td align="right">27</td>
<td align="right">310</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$16.0</td>
<td>$14.8</td>
<td>$15.8</td>
<td>$235.00</td>
<td>$185.4K</td>
<td align="right">85</td>
<td align="right">251</td>
</tr>
<tr>
<td>HUM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$7.3</td>
<td>$7.1</td>
<td>$7.1</td>
<td>$250.00</td>
<td>$122.1K</td>
<td align="right">517</td>
<td align="right">174</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$25.9</td>
<td>$25.7</td>
<td>$25.7</td>
<td>$240.00</td>
<td>$105.3K</td>
<td align="right">111</td>
<td align="right">42</td>
</tr>
<tr>
<td>HUM</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$9.6</td>
<td>$8.9</td>
<td>$9.6</td>
<td>$222.50</td>
<td>$96.0K</td>
<td align="right">40</td>
<td align="right">160</td>
</tr>
</tbody>
</table>

<h3>About Humana</h3>
Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Following our analysis of the options activities associated with Humana, we pivot to a closer look at the company's own performance.
<h3>Current Position of Humana</h3>
<ul>
<li>Trading volume stands at 992,527, with HUM's price up by 0.96%, positioned at $228.79.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 63 days.</li>
</ul>
<h3>Expert Opinions on Humana</h3>
Over the past month, 3 industry analysts have shared their insights on this stock, proposing an average target price of $301.67.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Neutral, adjusting the price target to $290. 
&#x2A; An analyst from Truist Securities persists with their Hold rating on Humana, maintaining a target price of $305. 
&#x2A; An analyst from Oppenheimer persists with their Outperform rating on Humana, maintaining a target price of $310. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Humana options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Options

This Is What Whales Are Betting On Humana

Whales with a lot of money to spend have taken a noticeably bullish stance on Coca-Cola.
Looking at options history for Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>) we detected 11 trades.
If we consider the specifics of each trade, it is accurate to state that 63% of the investors opened trades with bullish expectations and 27% with bearish.
From the overall spotted trades, 5 are puts, for a total amount of $248,160 and 6, calls, for a total amount of $254,425.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $52.5 and $75.0 for Coca-Cola, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Coca-Cola's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Coca-Cola's whale trades within a strike price range from $52.5 to $75.0 in the last 30 days. 
<h3>Coca-Cola Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748458858_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>KO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$3.45</td>
<td>$3.4</td>
<td>$3.45</td>
<td>$72.50</td>
<td>$81.4K</td>
<td>741</td>
<td align="right">266</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.13</td>
<td>$1.1</td>
<td>$1.13</td>
<td>$71.00</td>
<td>$79.0K</td>
<td>2.2K</td>
<td align="right">701</td>
</tr>
<tr>
<td>KO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/21/25</td>
<td>$2.2</td>
<td>$2.18</td>
<td>$2.18</td>
<td>$67.50</td>
<td>$62.1K</td>
<td>2.0K</td>
<td align="right">303</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$1.08</td>
<td>$1.05</td>
<td>$1.07</td>
<td>$72.00</td>
<td>$53.5K</td>
<td>2.2K</td>
<td align="right">10</td>
</tr>
<tr>
<td>KO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$20.0</td>
<td>$19.6</td>
<td>$19.65</td>
<td>$52.50</td>
<td>$39.3K</td>
<td>33</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h3>About Coca-Cola</h3>
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around two thirds of its total revenue overseas, with a significant portion from emerging economies in Latin America and Asia-Pacific.
After a thorough review of the options trading surrounding Coca-Cola, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Where Is Coca-Cola Standing Right Now?</h3>
<ul>
<li>With a trading volume of 4,664,873, the price of KO is down by -0.77%, reaching $71.22.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 55 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Coca-Cola</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $81.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Maintaining their stance, an analyst from RBC Capital continues to hold a Outperform rating for Coca-Cola, targeting a price of $76. 
&#x2A; An analyst from UBS persists with their Buy rating on Coca-Cola, maintaining a target price of $86. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Coca-Cola, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Looking At Coca-Cola's Recent Unusual Options Activity

7 analysts have expressed a variety of opinions on Tronox Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $8.5, a high estimate of $10.00, and a low estimate of $7.00. Experiencing a 30.38% decline, the current average is now lower than the previous average price target of $12.21. 
<img src="https://www.benzinga.com/files/images/story/2025/1748458854_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The analysis of recent analyst actions sheds light on the perception of Tronox Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Duffy Fischer</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$7.50</td>
<td>$11.50</td>
</tr>
<tr>
<td>Vincent Andrews</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$8.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Peter Osterland</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$9.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tronox Holdings. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tronox Holdings compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Tronox Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Tronox Holdings's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TROX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Tronox Holdings analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>All You Need to Know About Tronox Holdings</h2>
Tronox Holdings PLC is a vertically integrated manufacturer of TiO2 pigment. It operates titanium-bearing mineral sand mines and beneficiation and smelting operations in Australia &amp; South Africa to produce feedstock materials that can be processed into TiO2 for pigment, high-purity titanium chemicals, including titanium tetrachloride, and ultrafine TiO2 used in certain specialty applications. TiO2 and titanium feedstock, are used to produce paints and coatings, as well as plastics, paper, and printing ink. It has three pigment production facilities in the United States, the Netherlands, and Western Australia and three mining operations in Western Australia and South Africa. Europe, the Middle East, and Africa regions contribute the majority of revenue.
<h3>Key Indicators: Tronox Holdings's Financial Health</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Decline in Revenue: Over the 3M period, Tronox Holdings faced challenges, resulting in a decline of approximately -4.65% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.
Net Margin: Tronox Holdings's net margin is impressive, surpassing industry averages. With a net margin of -15.04%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tronox Holdings's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -6.46%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Tronox Holdings's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.83%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a high debt-to-equity ratio of 1.85, Tronox Holdings faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>How Are Analyst Ratings Determined?</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

TROX

Beyond The Numbers: 7 Analysts Discuss Tronox Holdings Stock

Whales with a lot of money to spend have taken a noticeably bearish stance on Celsius Holdings.
Looking at options history for Celsius Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) we detected 19 trades.
If we consider the specifics of each trade, it is accurate to state that 36% of the investors opened trades with bullish expectations and 63% with bearish.
From the overall spotted trades, 10 are puts, for a total amount of $587,270 and 9, calls, for a total amount of $408,526.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $50.0 for Celsius Holdings over the last 3 months. 
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Celsius Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Celsius Holdings's whale trades within a strike price range from $30.0 to $50.0 in the last 30 days. 
<h3>Celsius Holdings Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748458852_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$1.4</td>
<td>$1.16</td>
<td>$1.24</td>
<td>$36.50</td>
<td>$183.1K</td>
<td>412</td>
<td>3.0K</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$3.3</td>
<td>$3.1</td>
<td>$3.2</td>
<td>$50.00</td>
<td>$106.8K</td>
<td>9.3K</td>
<td>424</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/18/26</td>
<td>$4.8</td>
<td>$4.55</td>
<td>$4.8</td>
<td>$30.00</td>
<td>$88.8K</td>
<td>181</td>
<td>243</td>
</tr>
<tr>
<td>CELH</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/30/25</td>
<td>$1.32</td>
<td>$1.25</td>
<td>$1.31</td>
<td>$36.00</td>
<td>$65.5K</td>
<td>1.6K</td>
<td>579</td>
</tr>
<tr>
<td>CELH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$1.24</td>
<td>$1.24</td>
<td>$1.24</td>
<td>$40.00</td>
<td>$55.1K</td>
<td>56.7K</td>
<td>12.0K</td>
</tr>
</tbody>
</table>

<h3>About Celsius Holdings</h3>
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), Celsius On-the-Go powder packets, and soon-to-be-acquired Alani Nu energy drinks and snacks portfolio. Celsius dedicates its efforts to branding and innovation, while it largely utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.
Following our analysis of the options activities associated with Celsius Holdings, we pivot to a closer look at the company's own performance.
<h3>Where Is Celsius Holdings Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,044,854, with CELH's price down by -3.73%, positioned at $35.66.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 69 days.</li>
</ul>
<h3>Professional Analyst Ratings for Celsius Holdings</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $45.33.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Needham has decided to maintain their Buy rating on Celsius Holdings, which currently sits at a price target of $47. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on Celsius Holdings, maintaining a target price of $44. 
&#x2A; Reflecting concerns, an analyst from Needham lowers its rating to Buy with a new price target of $45.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Celsius Holdings options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

CELH

Unpacking the Latest Options Trading Trends in Celsius Holdings

During the last three months, 9 analysts shared their evaluations of Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $17.67, a high estimate of $25.00, and a low estimate of $12.00. A decline of 5.91% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1748458841_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The analysis of recent analyst actions sheds light on the perception of Bitdeer Technologies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Giles</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$18.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$20.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$17.00</td>
<td>$13.00</td>
</tr>
<tr>
<td>Mark Palmer</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$24.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$15.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$12.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>John Todaro</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$15.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Kevin Cassidy</td>
<td>Rosenblatt</td>
<td>Lowers</td>
<td>Buy</td>
<td>$25.00</td>
<td>$30.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Bitdeer Technologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bitdeer Technologies compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Bitdeer Technologies's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Bitdeer Technologies's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BTDR/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Bitdeer Technologies analyst ratings.</a>
<h2>Delving into Bitdeer Technologies's Background</h2>
Bitdeer Technologies Group is principally engaged in provision of digital asset mining services. The Company does not conduct any substantive operations on its own but conducts its primary operations through its subsidiaries. Its majority business segments are: proprietary mining, cloud hash rate sharing and cloud hosting. The company operates five proprietary mining datacenters in the United States and Norway, Bhutan and Singapore.
<h3>Key Indicators: Bitdeer Technologies's Financial Health</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Negative Revenue Trend: Examining Bitdeer Technologies's financials over 3M reveals challenges. As of 31 March, 2025, the company experienced a decline of approximately -41.32% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Bitdeer Technologies's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 583.89%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Bitdeer Technologies's ROE stands out, surpassing industry averages. With an impressive ROE of 76.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Bitdeer Technologies's ROA excels beyond industry benchmarks, reaching 25.94%. This signifies efficient management of assets and strong financial health.
Debt Management: Bitdeer Technologies's debt-to-equity ratio is below the industry average at 0.38, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

Western Resources

Notizie

Ultime notizie per Western Resources (OTC:WTRNF) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO